ITeos Therapeutics is throwing in the towel. | iTeos Therapeutics is throwing in the towel. Two weeks after axing its ...

Teos will look to distribute its cash reserves to shareholders, along with proceeds raised from selling pipeline assets.

Teos expects to absorb nearly $25 million in one-time costs for severance and termination payments. The biotech had 173 ...

US biotech iTeos Therapeutics (Nasdaq: ITOS) is preparing to wind down its operations and halt clinical work, as it looks to ...

Weeks after shelving a TIGIT drug prospect, the biotech is seeking to sell off its assets and intellectual property in a bid ...

GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a meaningful benefit in two Phase II trials. Belrestotug, a human IgG1 antibody ...

TIGIT drug collaboration. Company will wind down operations and sell assets, including EOS-984 and EOS-215 programs.

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston Pharmaceuticals, pledging another $800 million in milestone payments if the ...

Teos and GSK were the last to report a new setback in TIGIT targeting for non-small cell lung cancer patients. Read why I am ...

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...